NetWorth
LeaderPortfolio
Giuliani
Mario Germano Giuliani
Rank #1515
SWITZERLAND•Healthcare•Pharmaceuticals

Mario Germano Giuliani

Net Worth
$2.736B
-1.16% (24h)
Mario Germano Giuliani is a Swiss healthcare investor with an estimated net worth of $2.4 billion as of March 25, 2026. His wealth is primarily derived from his 8% stake in Royalty Pharma, the world's largest acquirer of pharmaceutical royalties. Giuliani also holds stakes in the Swiss investment company HBM Healthcare Investments and various U.S.-based biotech firms. He shares ownership of the family pharmaceutical company, Giuliani, founded in 1889 in Milan, Italy. Giuliani's career has been centered on managing inherited assets and fostering innovation in the healthcare sector.

How to read Mario Germano Giuliani's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Mario Germano Giuliani, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.736B alongside global rank #1515, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (SWITZERLAND) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Family Legacy

Mario Germano Giuliani, born in 1972, comes from a family deeply rooted in the pharmaceutical industry. His great-grandfather, Germano Giuliani, established the family's pharmaceutical company, Giuliani, in Milan, Italy, in 1889. The company's origins trace back to the Antica Farmacia del Lazzaretto, Milan's first pharmacy, where the first formulation of Amaro Medicinale was developed. Giuliani is a 100% Italian Pharmaceutical Company operating in the name of Innovation, Quality, Research and Integrity.

Rise to Success

The Giuliani family's wealth significantly increased through their investment in Royalty Pharma, a New York-based firm specializing in acquiring pharmaceutical royalties. Royalty Pharma went public in 2020, and Mario Giuliani's stake in the company is a key driver of his net worth. The family's long-term view on the investment in the Italian healthcare sector has been a core component of his investment strategy. Giuliani's expertise lies in long-term investment and innovation in the pharmaceutical and consumer goods sectors.

Key Business Strategies

Mario Germano Giuliani's business approach centers on preserving and growing the family's pharmaceutical legacy. This is achieved through strategic investments, with an emphasis on the development and commercialization of specialty drugs and consumer health products. He is the director of HBM Healthcare Investments AG since 2012, and has held numerous other director positions in the pharmaceutical and financial sectors. MGG Capital is the private investment company of Mario Germano Giuliani. MGG Capital supports entrepreneurs and management teams, who aspire to take their successful companies to the next level.

Philanthropy

Giuliani's philanthropy supports various community and educational initiatives. His structural contribution is tied to the successful generational transition and stable private control of a critical Italian industrial asset.

Career Timeline

2020-Present

Director at ElevateBio LLC

Served as a Director at ElevateBio LLC

2020-2024

Independent Director at Royalty Pharma Plc

Served as an Independent Director at Royalty Pharma Plc.

2015-Present

Member of the Board of Directors at MGG Capital SAM

Member of the Board of Directors at MGG Capital SAM.

2015-2016

Director at Nogra Group SA

Served as a Director at Nogra Group SA.

2012-Present

Director at HBM Healthcare Investments AG

Serving as a Director at HBM Healthcare Investments AG.

2011-2014

Director at Recordati SpA

Served as a Director at Recordati SpA.

2000-2010

Principal at Mosaix Ventures LLC

Held the position of Principal at Mosaix Ventures LLC

1996-2014

Executive positions and directorships at Giuliani SpA

Held executive positions and directorships within the family's pharmaceutical company.

Philanthropic Impact

Community and Education$XB

Community and educational initiatives

Supports various community and educational initiatives.

Key Business Ventures & Holdings

CompanyStakeValue
Royalty Pharma PLC8.00%$0.159M

Net Worth History

In-Depth Analysis

Early Life and Family Legacy

Mario Germano Giuliani, born in 1972, comes from a family deeply rooted in the pharmaceutical industry. His great-grandfather, Germano Giuliani, established the family's pharmaceutical company, Giuliani, in Milan, Italy, in 1889. The company's origins trace back to the Antica Farmacia del Lazzaretto, Milan's first pharmacy, where the first formulation of Amaro Medicinale was developed. Giuliani is a 100% Italian Pharmaceutical Company operating in the name of Innovation, Quality, Research and Integrity.

Rise to Success

The Giuliani family's wealth significantly increased through their investment in Royalty Pharma, a New York-based firm specializing in acquiring pharmaceutical royalties. Royalty Pharma went public in 2020, and Mario Giuliani's stake in the company is a key driver of his net worth. The family's long-term view on the investment in the Italian healthcare sector has been a core component of his investment strategy. Giuliani's expertise lies in long-term investment and innovation in the pharmaceutical and consumer goods sectors.

Key Business Strategies

Mario Germano Giuliani's business approach centers on preserving and growing the family's pharmaceutical legacy. This is achieved through strategic investments, with an emphasis on the development and commercialization of specialty drugs and consumer health products. He is the director of HBM Healthcare Investments AG since 2012, and has held numerous other director positions in the pharmaceutical and financial sectors. MGG Capital is the private investment company of Mario Germano Giuliani. MGG Capital supports entrepreneurs and management teams, who aspire to take their successful companies to the next level.

Philanthropy

Giuliani's philanthropy supports various community and educational initiatives. His structural contribution is tied to the successful generational transition and stable private control of a critical Italian industrial asset.

Data Sources & Methodology

Figures for Mario Germano Giuliani are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom